About King Whittle
The PRAC further considered that the risks of effects on the heart and circulation, and any potential mechanisms for such effects should continue to be monitored, and information from ongoing studies should be provided as part of the next regular safety review (to which these medicines, like all medicines in the EU, are subject). However, further studies are warranted to elucidate the risks of TRT in patients with significant CV risk factors and those with prior history of CV events. The results are very reassuring in that testosterone replacement does not increase overall cardiovascular risk in this group of patients with symptomatic hypogonadism and low testosterone level. A total of 5,246 men aged years with pre-existing or high risk of cardiovascular disease, symptoms of hypogonadism, and testosterone levels Results from the TRAVERSE trial were submitted in 2023, concluding that there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.Although rare, there is a potential for injury to underlying structures such as nerves, blood vessels, or muscle tissue. Modern surgical protocols significantly reduce infection risk. However, when performed by an experienced surgeon, complication rates remain low and outcomes are typically highly satisfactory.
The review was started because of some recent studies suggesting an increase in heart problems in men using testosterone, compared with men not using it. However, the product information is to be updated in line with the most current available evidence on safety, and with warnings that the lack of testosterone should be confirmed by signs and symptoms and laboratory tests before treating men with these medicines. It's normal for testosterone levels to decrease with age. Ask your provider how you should prepare for a testosterone levels test. You may be able to test your testosterone levels with an at-home kit. A health care professional will take a blood sample from a vein in your arm, using a small needle.
Other bias was judged to be high if the study was sponsored or done by a pharmaceutical company. A full list of secondary outcomes is available in the appendix (p 3). Primary outcomes and additional secondary outcomes were categorised independently by two clinical review authors (CJ, RQ). Physiological markers were reported as secondary outcomes (appendix p 3). If this was not possible, the research team discussed discrepancies and decided whether data should be included.
Dr. Moein highlights that patient education and proper surgical planning are key factors in minimizing these risks. Like all surgical procedures, gynecomastia surgery carries potential risks. The current guidelines recommend no clear evidence of CV risk for any given group of patients treated with TRT.